http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 17:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680474.html si-local-file:///var/storage/secattach/20260623/26680474.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680474.html Tue, 23 Jun 2026 17:10:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680474.html si-local-file:///var/storage/secattach/20260623/26680474.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680474.html Tue, 23 Jun 2026 17:10:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Aug+14/26680468.html si-local-file:///var/storage/secattach/20260623/26680468.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Aug+14/26680468.html Tue, 23 Jun 2026 17:09:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Aug+14/26680468.html si-local-file:///var/storage/secattach/20260623/26680468.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Aug+14/26680468.html Tue, 23 Jun 2026 17:09:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680370.html si-local-file:///var/storage/secattach/20260623/26680370.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680370.html Tue, 23 Jun 2026 17:00:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680370.html si-local-file:///var/storage/secattach/20260623/26680370.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++NEONC+TECHNOLOGIES+HOLDI+++++++++++++/26680370.html Tue, 23 Jun 2026 17:00:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Jun+23/26680375.html si-local-file:///var/storage/secattach/20260623/26680375.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Jun+23/26680375.html Tue, 23 Jun 2026 17:00:00 -0400 NTHI O.71329185 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Jun+23/26680375.html si-local-file:///var/storage/secattach/20260623/26680375.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NEONC+TECHNOLOGIES+HOLDI++For%3A+Jun+23/26680375.html Tue, 23 Jun 2026 17:00:00 -0400 NTHI O.71329185 http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/FDA/NeOnc+gets+UAE+approval+for+NEO100+brain+cancer+drug+trials/26676787.html <p>NeOnc Technologies Holdings (Nasdaq: NTHI) announced that the Department of Health – Abu Dhabi has granted Investigational New Drug status for NEO100, its intranasal formulation of purified perillyl alcohol intended for nose-to-brain delivery in patients with brain cancer.</p> <p>The authorization covers three protocols — NEO100-01, NEO100-02, and NEO100-03 — spanning Phase 1, Phase 1b, and Phase 2 studies in adults, along with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. The authorized indication is progressive or recurrent Grade III or IV gliomas.</p> <p>The approval follows a separate IND clearance granted by the same authority for NeOnc's NEO212 http://www.streetinsider.com/FDA/NeOnc+gets+UAE+approval+for+NEO100+brain+cancer+drug+trials/26676787.html Tue, 23 Jun 2026 09:00:26 -0400 NTHI http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Receives+UAE+IND+Approval+for+NEO100%2C+Expanding+Global+Development+Ahead+of+Anticipated+Phase+2+Data+Milestone/26676713.html <p align="center"><em>Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies</em></p> <p align="center"><em>Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations</em></p> <p>CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead http://www.streetinsider.com/Press+Releases/NeOnc+Technologies+Receives+UAE+IND+Approval+for+NEO100%2C+Expanding+Global+Development+Ahead+of+Anticipated+Phase+2+Data+Milestone/26676713.html Tue, 23 Jun 2026 09:00:00 -0400 NTHI http://www.streetinsider.com/Globe+Newswire/NeOnc+Technologies+Receives+UAE+IND+Approval+for+NEO100%2C+Expanding+Global+Development+Ahead+of+Anticipated+Phase+2+Data+Milestone/26676713.html <p align="center"><em>Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies</em></p> <p align="center"><em>Extends NeOnc’s UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations</em></p> <p>CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company’s lead http://www.streetinsider.com/Globe+Newswire/NeOnc+Technologies+Receives+UAE+IND+Approval+for+NEO100%2C+Expanding+Global+Development+Ahead+of+Anticipated+Phase+2+Data+Milestone/26676713.html Tue, 23 Jun 2026 09:00:00 -0400 NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Press+Releases/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html <p><strong>NTHI Joins a Growing Group of Companies Pursuing Parallel Global Regulatory Strategies</strong></p><p>DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=E1d5z6LUlH_K1HOWFKfhn-P7_wRqqy87ZwPvMV2hVFinw6LML377O6dz0OxbfmFljRo67oX7wlv5bf_9pXFT8Qeb4q9QJHF6js87aUHkQ7k=" rel="nofollow" target="_blank"><u>247marketnews.com</u></a>) -- <a href="https://www.globenewswire.com/Tracker?data=xRpwuIQpo7t6bXKwPfkQsUEfl5Hn-GKsl_3eyyQ5VhrRGHXjZFXg8StUN6GkBVqtt9gZwviGvTTpYsvmE7TusrdcQ5HvBbCxY4MWvoCmmKncg3vA1JBI7J0Ku3wTcmrC" rel="nofollow" target="_blank"><strong>NeOnc Technologies Holdings</strong></a><strong> (NASDAQ: NTHI)</strong> remains an early-stage biotechnology company, but the recent Abu Dhabi IND authorization for NEO212 highlights a development strategy that has become increasingly attractive across the pharmaceutical industry: pursuing regulatory and clinical opportunities in multiple jurisdictions while advancing toward larger milestones in the United States.</p> <p>Historically, international regulatory progress has often preceded expedited FDA reviews, expanded clinical programs, and, in some cases, significant commercial outcomes.</p> <p>One http://www.streetinsider.com/Globe+Newswire/International+Regulatory+Pathways+Have+Supported+Drug+Development+Across+Biotech+and+Pharma/26670824.html Mon, 22 Jun 2026 09:05:00 -0400 BBIO BIIB LLY NTHI